<DOC>
	<DOCNO>NCT00783653</DOCNO>
	<brief_summary>In study safety tolerability two dose level SU 11248 ( sutent ) standard chemotherapy patient FLT3 mutate AML 60 year evaluate .</brief_summary>
	<brief_title>Clinical Study SU 11248 ( Sutent ) Combined With Standard Chemotherapy Patients With FLT3 Mutated AML Over 60 Years</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients primary secondary acute myeloid leukemia ( FAB type , except M3 ) . No prior systemic chemotherapy AML except hydroxyurea . Cytoreductive therapy hydroxyurea recommend WBC &gt; 50.000/Âµl , cease least one day prior start study medication Patient age equal great 60 year Patients must FLT3 mutate AML , either ITD kinase domain mutation ECOG Performance score 3 less ( Karnofsky Performance Score &gt; 40 % ) . Life expectancy four week . Adequate hepatic renal function , define serum transaminase &lt; 2.5x ULN , bilirubin &lt; 1.5x ULN . Creatinine &lt; 1.5x ULN . Patients must provide write informed consent participate trial . Normal heart function cardiac ultrasound Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; =1.5 x ULN Serum albumin &gt; =3.0 g/dl Serum amylase lipase &lt; =1.0 x ULN Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . The presence follow exclude subject study enrollment : Treatment investigational agent within four week . Known HIV infection Presence medical psychiatric condition may limit full compliance study , include limited : Presence CNS leukaemia Unresolved toxicity previous anticancer therapy incomplete recovery surgery . Any follow within 12 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis , thromboembolic event . Current treatment therapeutic dos anticoagulant ( low dose Coumadin 2 mg PO daily deep vein thrombosis prophylaxis allow ) . Hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) . Pre exist thyroid abnormality thyroid function maintain normal range medication . Ongoing cardiac dysrhythmias NCI CTCAE Grade &gt; =2 , atrial fibrillation Grade , prolongation QTc interval &gt; 450 msec male &gt; 470 msec female . Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>AML</keyword>
	<keyword>FLT3</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>FLT 3 inhibitor</keyword>
	<keyword>FLT3 mutate AML</keyword>
</DOC>